Renaissance Capital logo

MXCT News

US IPO Weekly Recap: Biotechs pop and Robinhood flops in a record 20 IPO week

ICVX

The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed, citing either volatility or market conditions: vehicle battery maker Clarios International (BTRY), specialty...read more

AIM-listed cell engineering platform MaxCyte prices upsized US IPO at $13, within the range

MXCT

MaxCyte, which provides cell engineering devices and services, raised $176 million by offering 13.5 million shares at $13, within the range of $11.50 to $13.50. The company offered 1.5 million more shares than anticipated. MaxCyte's Flow Electroporation technology facilitates the complex engineering of a variety of cells. It uses electroporation, which is the process of applying...read more

AIM-listed cell engineering platform MaxCyte sets terms for $150 million US IPO

MXCT

MaxCyte, which provides cell engineering devices and services, announced terms for its IPO on Monday. The Gaithersburg, MD-based company plans to raise $150 million by offering 12 million shares at a price range of $11.50 to $13.50. The company is currently listed on London's AIM market under the symbols "MXCT" and "MXCN". At the midpoint of the proposed range, MaxCyte would...read more

AIM-listed cell engineering platform MaxCyte files for a $100 million US IPO

MXCT

MaxCyte, which provides cell engineering devices and services, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company is currently listed on London's AIM (MXCT). MaxCyte's Flow Electroporation technology facilitates the complex engineering of a variety of cells. It uses electroporation, which is the process of applying an electric...read more

Archived Headlines